Strengthening the Future of BRII-179
Brii Biosciences Limited has announced a landmark agreement to acquire the intellectual property rights related to BRII-179, a decisive move for the biotechnology firm focused on addressing unmet medical needs. This acquisition has granted Brii comprehensive control over future manufacturing and supply of BRII-179, ensuring a seamless path for its continued development and clinical supply.
The Potential of BRII-179
BRII-179 represents a promising avenue for patients struggling with chronic Hepatitis B Virus (HBV) infection. The company has accelerated its strategy to develop combination therapies utilizing BRII-179, targeting improved therapeutic outcomes for those affected by this significant global health concern. With over 254 million people worldwide diagnosed with HBV, the urgency to find effective treatments is paramount.
Elimination of Future Obligations
With this agreement, Brii has relieved itself of future milestone and royalty obligations owed to VBI Vaccines, Inc. The financial terms involve a total payment of US$18 million for the complete acquisition of all related patents and proprietary technologies. This strategic decision positions Brii alongside its shareholders, reinforcing the value of BRII-179 as the company moves toward late-stage development.
Details on BRII-179
BRII-179 is a cutting-edge immunotherapeutic candidate designed to stimulate the immune system's response to HBV. By expressing the surface antigens Pre-S1, Pre-S2, and S, it aims to enhance both B-cell and T-cell immunity, allowing for a more targeted and effective approach to managing HBV infections. Recently, the Center for Drug Evaluation recognized BRII-179 with a Breakthrough Therapy Designation, a testament to its potential impact on public health.
Ongoing Research and Development
Brii Bio has already initiated several clinical studies leveraging BRII-179, focusing primarily on combination treatments to increase the functional cure rate of chronic HBV infections. The ongoing ENRICH study, which examines a combination of BRII-179, elebsiran, and PEG-IFN?, has successfully completed patient enrollment, demonstrating confidence in this novel treatment regimen.
Understanding Hepatitis B
Hepatitis B remains one of the leading infectious disease challenges, particularly given its role in liver disease. Each year, complications from chronic HBV result in an estimated 820,000 deaths globally. In regions where the prevalence is particularly high, such as certain areas in Asia, efforts to find viable treatments are critical. Community outreach and education play a significant role in combating the stigma often associated with this virus, which can hinder treatment uptake.
About Brii Bio
Brii Biosciences Limited is dedicated to developing innovative therapies that address major health challenges. With core competencies in infectious and neurodegenerative diseases, the company aims to improve health outcomes and expand treatment options for patients facing high unmet medical needs. Led by a team of seasoned experts, Brii operates in vital biopharmaceutical hubs and pursues a diverse pipeline of therapeutic candidates.
Frequently Asked Questions
What is BRII-179?
BRII-179 is an investigational immunotherapeutic candidate targeting chronic Hepatitis B Virus infections, designed to boost the immune response.
Why is Brii Bio's acquisition of BRII-179 significant?
This acquisition allows Brii complete control over BRII-179's intellectual property and paves the way for uninterrupted clinical development.
How does BRII-179 aim to help patients?
The drug focuses on enhancing immune responses to HBV and is part of a strategy to improve functional cure rates among patients.
What clinical studies is Brii Bio currently conducting?
Brii Bio is currently conducting combination studies using BRII-179 to determine its effectiveness in treating chronic HBV.
What designations has BRII-179 received?
BRII-179 has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation, highlighting its potential therapeutic benefits for patients.
